Gapping up
In reaction to strong earnings/guidance:
- OPCH +25.6%, HLIT +15.7%, AVT +11.3% (guides JunQ above consensus), JELD +8.4%, SEDG +8.3%, MOS +8.1%, SPNS +8.1%, IPHI +7.2%, VRNS +6.5%, BP +6.5%, TXRH +6.4%, IGT +6.2%, USFD +5.5%, WBT +5.3%, AMCX +5.3%, VNO +5%, IT +5%, BRX +4.9%, SYKE +4.9%, TTWO +4.8%, RCM +4.7%, LGIH +4.5%, AMRC +4.2%, FRPT +3.7%, OTTR +3.7%, PRIM +3.4%, ACM +3.1%, UGI +3%, SNE +3%, EMR +2.6%, VMC +2.5%, HHC +2.4%, WMG +2.3%, TECH +2.2%, VSH +2.2%, INCY +2.2%, DOOR +2%, FIVN +1.9%, FIS +1.9%, LDOS +1.7%, IAA +1.4%, ICHR +1.3% (also files for $200 mln mixed shelf offering), IR +1.3%, KKR +1.3%, O +1.2%, NBIX +1.2%, HSIC +1.2%, NEX +1.1%, AME +1.1%
Other news:
- ELOX +13.2% (receives orphan drug designation from the FDA for ELX-02 for the treatment of cystic fibrosis)
- TLSA +9.5% (expedites clinical development plan for its anti-interleukin-6-receptor)
- CAMP +7% (names Amal Johnson as Chair of the Board)
- EXPI +4.7% (acquires assets of Showcase IDX)
- ABMD +2% (FDA has issued an EUA for left-sided Impella heart pumps to provide left ventricular unloading and support to COVID-19 patients who are undergoing ECMO treatment and develop pulmonary edema or myocarditis)
- ONTO +1.8% (announces multiple orders for JetStep)
- RGNX +1.5% (reported positive one year data from patients in Cohorts 4 and 5 of the Phase I/IIa trial of RGX-314 for the treatment of wet age-related macular degeneration) ONE +1.4% (reports that it has reopened more than 90% of its nationwide learning centers)
- ZLAB +1.2% (granted priority review status to the New Drug Application for ripretinib from the Center for Drug Evaluation of China's National Medical Products Administration)
Analyst comments:
- BRKS +1.3% (upgraded to Buy from Hold at Needham)
- Z +0.7% (upgraded to Neutral from Negative at Susquehanna)
- RS +0.6% (upgraded to Buy from Hold at Deutsche Bank)